Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) Short Interest Update

Swedish Orphan Biovitrum AB (publ) (OTCMKTS:BIOVF) was the recipient of a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 779,800 shares, an increase of 35.9% from the February 28th total of 573,800 shares. Approximately 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 100 shares, the days-to-cover ratio is presently 7,798.0 days.

Analyst Ratings Changes

Separately, Barclays upgraded shares of Swedish Orphan Biovitrum AB (publ) to a “strong-buy” rating in a research report on Wednesday, January 8th.

Swedish Orphan Biovitrum AB (publ) Stock Performance

Shares of OTCMKTS BIOVF opened at $28.71 on Monday. The company has a debt-to-equity ratio of 0.31, a current ratio of 0.91 and a quick ratio of 0.62. Swedish Orphan Biovitrum AB has a one year low of $22.87 and a one year high of $32.25. The business’s 50-day moving average price is $29.62 and its two-hundred day moving average price is $29.55. The company has a market capitalization of $10.22 billion, a P/E ratio of 27.61 and a beta of 0.62.

Swedish Orphan Biovitrum AB (publ) Company Profile

Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); VONJO for the treatment of adults with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis; Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still’s disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.